Ascendis Pharma (ASND) announced the FDA has accepted for priority review its New Drug Application for TransCon CNP for the treatment of children with achondroplasia and has set a PDUFA goal date of November 30, 2025 to complete its review. The FDA also informed Ascendis that they are not currently planning to hold an advisory committee meeting to discuss this application.
TransCon CNP is an investigational prodrug of C-type natriuretic peptide administered once weekly and designed to treat people living with achondroplasia.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.